Supernus Pharmaceuticals, Inc. notified Nasdaq of the completion of its merger on November 2, 2026, and requested the suspension and delisting of its common stock. The company intends to deregister its shares and suspend its reporting obligations under the Exchange Act as it will no longer be listed on any national securities exchange.
Supernus Pharmaceuticals M&A Deal with Indivior Pharmaceuticals, Inc.
Supernus Pharmaceuticals completed its previously announced merger with Indivior Pharmaceuticals, with Supernus becoming a wholly owned subsidiary of the combined entity, which has been renamed Supernus, Inc. Supernus stockholders received 1.5401 shares of the combined company for each share held, and the transaction was supported by a new $650 million senior secured term loan facility.
Supernus Pharmaceuticals reported total revenues of $226.8 million for the third quarter of 2026, driven by net product sales and collaboration revenue from ZURZUVAE. While the company achieved net earnings of $20.9 million for the quarter, it recorded a net loss of $39.8 million for the first nine months of 2026, primarily due to $56.5 million in impairment charges.
Supernus Pharmaceuticals reported record Q3 2026 total revenues of $226.8 million, an 18% increase year-over-year, driven by strong performance from growth products like Qelbree and ZURZUVAE. The company also announced that its pending merger with Indivior Pharmaceuticals is expected to close on November 2, 2026. Additionally, the FDA recognized seven years of orphan-drug exclusivity for its Parkinson’s disease treatment, ONAPGO.
Counterparty
Indivior Pharmaceuticals, Inc.
Term
Q3 2026
“Our strong operating execution year-to-date delivered total revenue growth of 29%, which shows the continued momentum across our commercial portfolio, specifically our growth products. We look forward to closing the merger with Indivior next week, which will create a diverse CNS biopharmaceutical leader positioned to serve more patients and deliver long-term value for shareholders.”
Jack Khattar, President and Chief Executive Officer
Supernus Pharmaceuticals Deal Termination with UBS Bank USA
Supernus Pharmaceuticals terminated its uncommitted demand revolving credit line with UBS Bank USA on October 20, 2026. The termination was made in anticipation of the company's pending merger with Indivior Pharmaceuticals and the establishment of a new senior secured credit facility for the combined entity. There were no outstanding borrowings or early termination penalties associated with the cancellation.
The FDA has recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in advanced Parkinson’s disease. The exclusivity period is retroactive to the drug's approval date of February 3, 2025, and the company has also submitted an sNDA for a second supplier to ensure long-term supply stability.
Term
7 years
“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community.”
Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals
Supernus Pharmaceuticals M&A Deal with Indivior Pharmaceuticals Inc.
Supernus Pharmaceuticals stockholders approved the company's acquisition by Indivior Pharmaceuticals at a special meeting held on October 15, 2026. Under the terms of the merger agreement, Supernus will become a wholly-owned subsidiary of Indivior. Stockholders also approved, on a non-binding basis, the merger-related compensation for the company's named executive officers.